Andrew J Yee
Massachusetts General Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrew J Yee as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:36 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07032714 · Mezigdomide and Talquetamab in Relapsed and Refractory Multiple MyelomaMassachusetts General Hospital · recruiting · Relapsed Refractory Multiple Myeloma (RRMM) · principal investigator
- Ph2NCT04176718 · Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MMAndrew Yee, MD · active not recruiting · Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse · principal investigator
- Ph1NCT03657420 · Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple MyelomaMassachusetts General Hospital · withdrawn · Multiple Myeloma · principal investigator
- Ph2NCT02718833 · A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple MyelomaMassachusetts General Hospital · active not recruiting · Multiple Myeloma · principal investigator
- Ph1NCT01562405 · Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple MyelomaMassachusetts General Hospital · active not recruiting · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:36 UTC. The ranking covers the 200 most relevant of 28 PubMed records, and a shared surname and initials can bring in a namesake. All 28 on PubMed
- Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.N Engl J Med · 2019550 citationsRCR 19.6
- 433 citationsRCR 32.2
- Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.Lancet Oncol · 2016172 citationsRCR 5.3
- A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.Br J Haematol · 2018147 citationsRCR 5.0
- Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.J Clin Oncol · 2018140 citationsRCR 4.6
- Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.Blood Adv · 202377 citationsRCR 5.8
- 74 citationsRCR 2.2
- Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body 18F-Florbetapir PET/CT.J Nucl Med · 201974 citationsRCR 3.8
- Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.Br J Haematol · 201858 citationsRCR 2.1
- A randomized trial of hydroxyapatite coated prostheses in total hip arthroplasty.Clin Orthop Relat Res · 199952 citationsRCR 3.5